PMC PharMerica Corporation

Bragar Eagel & Squire, P.C. Is Investigating the Board of Directors of PharMerica Corporation (PMC) on Behalf of Stockholders and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)--

Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of PharMerica Corporation (NYSE: PMC) stockholders concerning the proposed acquisition of the company by KKR & Co. L.P. (NYSE: KKR) and Walgreens Boots Alliance, Inc. (NASDAQ: WBA).

The investigation concerns whether PharMerica Corporation’s board of directors failed to adequately shop the Company and obtain the best possible value for PharMerica stockholders before entering into a definitive merger agreement with KKR and Walgreens Boots Alliance. Under the terms of the agreement, PharMerica Corporation stockholders will receive $29.25 in cash for each share of PharMerica common stock upon closing of the proposed transaction.

If you own PharMerica shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation of PharMerica Corporation, please go to http://www.bespc.com/pharmerica. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com.

EN
03/08/2017

Underlying

PMCPharMerica Corporation

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PharMerica Corporation

 PRESS RELEASE
Free
PMC PharMerica Corp...

KKR Completes Acquisition of PharMerica

LOUISVILLE, Ky.--(BUSINESS WIRE)-- PharMerica Corporation (NYSE:PMC) today announced the completion of the acquisition of PharMerica by a newly formed company controlled by KKR with an affiliate of Walgreens Boots Alliance, Inc. (Nasdaq: WBA) as a minority investor. As a result of the completion of the acquisition, PharMerica shareholders will receive an amount in cash equal to $29.25 per share of PharMerica common stock, without interest. In connection with the completion of the acquisition, shares of PharMerica’s common sto...

December 7, 2017 1 EN
 PRESS RELEASE
Free
PMC PharMerica Corp...

PharMerica Reports Third Quarter 2017 Results

LOUISVILLE, Ky.--(BUSINESS WIRE)-- PharMerica Corporation (NYSE: PMC), a national provider of institutional, specialty home infusion, hospital and oncology pharmacy services, today reported its financial results for the third quarter ended September 30, 2017. Third Quarter 2017 Results The results for the third quarter of 2017 are set forth below: Key Comparisons of Third Quarters Ended September 30, 2017 and 2016: Revenues for the third quarter of 2017 were $595.1...

November 9, 2017 1 EN
 PRESS RELEASE
Free
PMC PharMerica Corp...

PharMerica Announces Approval of Merger by Stockholders

LOUISVILLE, Ky.--(BUSINESS WIRE)-- PharMerica Corporation (NYSE: PMC), announced that at its special meeting of stockholders held today, a majority of the outstanding shares of PharMerica common stock voted to approve the adoption of the previously disclosed definitive merger agreement pursuant to which a newly formed company controlled by KKR, with Walgreens Boots Alliance, Inc. (Nasdaq: WBA) as a minority investor, will acquire PharMerica. The closing of the transaction remains subject to customary closing conditions. ...

November 9, 2017 1 EN
Free Trial
PMC PharMerica Corp...

PHARMERICA CORP. reduces its risk exposure and slightly improves to Ne...

The independent financial analyst theScreener just allocated a lower risk rating to PHARMERICA CORP. (US), active in the Health Care Providers industry. As regards its fundamental valuation, the title still shows 3 out of 4 possible stars. Its market behaviour, however, has slightly improved and can be qualified as moderately risky. theScreener considers that these elements merit an overall rating upgrade to Neutral. As of the analysis date October 27, 2017, the closing price was USD 29.10 and i...

PMC PHARMERICA CORPORATION
10/28/17 October 28, 2017 6 EN
 PRESS RELEASE
Free
PMC PharMerica Corp...

Onco360 Selected for VERZENIO® Limited Distribution Pharmacy Network

LOUISVILLE, Ky.--(BUSINESS WIRE)-- Onco360, the nation’s largest independent Oncology Pharmacy, announced today that it has been selected to participate in the limited distribution network for Eli Lilly and Company’s new product, VERZENIOTM (Abemaciclib), a twice daily oral cyclin-dependent kinase (CDK) 4/6 inhibitor approved by the U.S. Food and Drug Administration (FDA). VERZENIO is used in combination with fulvestrant to treat women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanc...

October 16, 2017 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch